-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Innovation is the eternal theme of the development of biopharmaceutical enterprises
.
In recent years, Chengdu's biopharmaceutical industry has risen rapidly and has become an important pole of China's biopharmaceutical landscape
.
From the perspective of R&D investment, Chengdu pharmaceutical and biological listed companies have invested heavily in R&D: the median of R&D expenditure (as a proportion of sales revenue) in the past five years has reached 6.
1%, which is higher than the national median of 4.
9%
.
For the development of the biopharmaceutical industry, Chengdu has also continuously introduced new policies
.
For example, in 2019, Chengdu issued two documents, "Implementation Opinions on Promoting the High-Quality Development of Chengdu's Pharmaceutical and Health Industry" and "Several Policies for Promoting the High-quality Development of Chengdu's Biomedical Industry" (hereinafter referred to as "Several Policies"), proposing to build a medical and health industry.
Highland, and clear development goals, by 2025, the operating income of the biopharmaceutical industry will reach 1 trillion yuan
.
This means that the biopharmaceutical industry has become the next trillion-level industry that Chengdu will focus on
.
Under the support and guidance of good development soil and favorable policies, Chengdu's biopharmaceutical industry has basically formed a relatively complete industrial system covering medicinal material planting and breeding, pharmaceutical R&D and manufacturing, pharmaceutical commerce and trade, medical services, and health services.
The circle continues to expand and the industrial chain continues to strengthen
.
In 2022, Chengdu will vigorously promote the establishment of a strong chain in the biopharmaceutical industry.
In terms of the innovative drug industry chain, Chengdu will focus on the development of small molecule targeted drugs, antibody drugs, and new vaccines
.
It is understood that there are constantly new news in the field of medicine in Chengdu
.
For example, on April 22, Chengdu signed an online contract with AstraZeneca's Traditional Chinese Medicine Innovation Industry Base, marking that Sichuan Province, with a multinational Fortune 500 pharmaceutical company as the "chain master", officially settled in Chengdu as an innovation base focusing on the field of traditional Chinese medicine
.
The base will feature the modernization of traditional Chinese medicine industry, relying on academicians and experts to drive scientific research transformation and industrial development, and build a one-stop Chinese medicine incubation industry empowerment platform in the west, which mainly includes a new R&D institution centered on academicians and experts, a modernized An innovative TCM industry service platform, a one-stop TCM clinical R&D transformation platform, and a TCM modern business platform
.
For another example, on March 23, the National Precision Medicine Industry Innovation Center was inaugurated in Chengdu Tianfu International Biological City, which is also the first national industrial innovation center in Sichuan Province
.
It is reported that the National Precision Medicine Industry Innovation Center will build three key common technology platforms for precise diagnosis, precise treatment, and precise evaluation, and a support platform for precision medicine strategic resource pools to promote scientific and technological innovation, achievement transfer and industrialization, and form a group of " The key core technology of "stuck neck"
.
At present, the total initial investment of the project is 1.
052 billion yuan
.
It is expected that in the next 3-5 years, the center will drive the output value of the precision medicine industry to exceed 100 billion yuan
.
In addition, there are also these key projects and major events in Chengdu recently, such as the establishment of the National Engineering Research Center for Isotopes and Drugs in Chengdu, the launch of the “In-depth Cooperation Project for Cell Therapy in the Greater Bay Area” in the west, and the Chengdu Medical City being selected as the tenth batch of national new industrialization industries.
The list of demonstration bases.
.
.
According to the industry, in recent days, key projects and major events in Chengdu's pharmaceutical and health industry have appeared frequently, which reflects the accelerated development of its pharmaceutical industry
.
The pharmaceutical industry has become a key area in Chengdu's charter
.
In 2022, Chengdu will promote the high-quality development of the industry, and it has set a clear goal: by 2025, it will cultivate two trillion-level, advanced manufacturing clusters in electronic information and equipment manufacturing, and create national advanced manufacturing industries such as aerospace, rail transit, and medicine and health.
cluster
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
.
In recent years, Chengdu's biopharmaceutical industry has risen rapidly and has become an important pole of China's biopharmaceutical landscape
.
From the perspective of R&D investment, Chengdu pharmaceutical and biological listed companies have invested heavily in R&D: the median of R&D expenditure (as a proportion of sales revenue) in the past five years has reached 6.
1%, which is higher than the national median of 4.
9%
.
For the development of the biopharmaceutical industry, Chengdu has also continuously introduced new policies
.
For example, in 2019, Chengdu issued two documents, "Implementation Opinions on Promoting the High-Quality Development of Chengdu's Pharmaceutical and Health Industry" and "Several Policies for Promoting the High-quality Development of Chengdu's Biomedical Industry" (hereinafter referred to as "Several Policies"), proposing to build a medical and health industry.
Highland, and clear development goals, by 2025, the operating income of the biopharmaceutical industry will reach 1 trillion yuan
.
This means that the biopharmaceutical industry has become the next trillion-level industry that Chengdu will focus on
.
Under the support and guidance of good development soil and favorable policies, Chengdu's biopharmaceutical industry has basically formed a relatively complete industrial system covering medicinal material planting and breeding, pharmaceutical R&D and manufacturing, pharmaceutical commerce and trade, medical services, and health services.
The circle continues to expand and the industrial chain continues to strengthen
.
In 2022, Chengdu will vigorously promote the establishment of a strong chain in the biopharmaceutical industry.
In terms of the innovative drug industry chain, Chengdu will focus on the development of small molecule targeted drugs, antibody drugs, and new vaccines
.
It is understood that there are constantly new news in the field of medicine in Chengdu
.
For example, on April 22, Chengdu signed an online contract with AstraZeneca's Traditional Chinese Medicine Innovation Industry Base, marking that Sichuan Province, with a multinational Fortune 500 pharmaceutical company as the "chain master", officially settled in Chengdu as an innovation base focusing on the field of traditional Chinese medicine
.
The base will feature the modernization of traditional Chinese medicine industry, relying on academicians and experts to drive scientific research transformation and industrial development, and build a one-stop Chinese medicine incubation industry empowerment platform in the west, which mainly includes a new R&D institution centered on academicians and experts, a modernized An innovative TCM industry service platform, a one-stop TCM clinical R&D transformation platform, and a TCM modern business platform
.
For another example, on March 23, the National Precision Medicine Industry Innovation Center was inaugurated in Chengdu Tianfu International Biological City, which is also the first national industrial innovation center in Sichuan Province
.
It is reported that the National Precision Medicine Industry Innovation Center will build three key common technology platforms for precise diagnosis, precise treatment, and precise evaluation, and a support platform for precision medicine strategic resource pools to promote scientific and technological innovation, achievement transfer and industrialization, and form a group of " The key core technology of "stuck neck"
.
At present, the total initial investment of the project is 1.
052 billion yuan
.
It is expected that in the next 3-5 years, the center will drive the output value of the precision medicine industry to exceed 100 billion yuan
.
In addition, there are also these key projects and major events in Chengdu recently, such as the establishment of the National Engineering Research Center for Isotopes and Drugs in Chengdu, the launch of the “In-depth Cooperation Project for Cell Therapy in the Greater Bay Area” in the west, and the Chengdu Medical City being selected as the tenth batch of national new industrialization industries.
The list of demonstration bases.
.
.
According to the industry, in recent days, key projects and major events in Chengdu's pharmaceutical and health industry have appeared frequently, which reflects the accelerated development of its pharmaceutical industry
.
The pharmaceutical industry has become a key area in Chengdu's charter
.
In 2022, Chengdu will promote the high-quality development of the industry, and it has set a clear goal: by 2025, it will cultivate two trillion-level, advanced manufacturing clusters in electronic information and equipment manufacturing, and create national advanced manufacturing industries such as aerospace, rail transit, and medicine and health.
cluster
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
